However, although dozens of inhibitors targeting STAT3 or its upstream pathways have been tested in clinical trials, only a few are approved by the United States Food and Drug Administration (FDA) for treatment of cancers including pancreatic cancer and gastric/gastroesophageal junction cancer, but not TNBC yet. The gene discussed is STAT3; the disease is cancer.